At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Laboratory Biomarker Analysis for Malignant Salivary Gland Neoplasm and 3 related conditions. Completed, enrolled 55 participants across 34 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartMar 2009
Primary CompletionJan 2013
TodayJul 2026
First PostedMar 11, 2009
Enrollment StartMar 16, 2009
Primary CompletionJan 30, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.3 years ago
Interventions
Dasatinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies